JP2013545438A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545438A5
JP2013545438A5 JP2013527629A JP2013527629A JP2013545438A5 JP 2013545438 A5 JP2013545438 A5 JP 2013545438A5 JP 2013527629 A JP2013527629 A JP 2013527629A JP 2013527629 A JP2013527629 A JP 2013527629A JP 2013545438 A5 JP2013545438 A5 JP 2013545438A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
bispecific construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013527629A
Other languages
English (en)
Japanese (ja)
Other versions
JP6173911B2 (ja
JP2013545438A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/065697 external-priority patent/WO2012032181A2/en
Publication of JP2013545438A publication Critical patent/JP2013545438A/ja
Publication of JP2013545438A5 publication Critical patent/JP2013545438A5/ja
Application granted granted Critical
Publication of JP6173911B2 publication Critical patent/JP6173911B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013527629A 2010-09-10 2011-09-09 抗体誘導体 Expired - Fee Related JP6173911B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38178910P 2010-09-10 2010-09-10
US61/381,789 2010-09-10
PCT/EP2011/065697 WO2012032181A2 (en) 2010-09-10 2011-09-09 Novel antibody derivatives

Publications (3)

Publication Number Publication Date
JP2013545438A JP2013545438A (ja) 2013-12-26
JP2013545438A5 true JP2013545438A5 (enExample) 2014-10-23
JP6173911B2 JP6173911B2 (ja) 2017-08-09

Family

ID=44583080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527629A Expired - Fee Related JP6173911B2 (ja) 2010-09-10 2011-09-09 抗体誘導体

Country Status (5)

Country Link
US (2) US20140127209A1 (enExample)
EP (1) EP2640745B1 (enExample)
JP (1) JP6173911B2 (enExample)
CN (1) CN103261222B (enExample)
WO (1) WO2012032181A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
US10039802B2 (en) * 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
AU2012278802B2 (en) 2011-07-06 2015-11-26 Société des Produits Nestlé S.A. Assays for detecting neutralizing autoantibodies to biologic therapy with TNF alpha
EP2583979B1 (en) 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
NZ700802A (en) 2012-05-03 2017-06-30 Boehringer Ingelheim Int Anti-il-23p19 antibodies
ES2718478T3 (es) * 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
SG11201501464TA (en) 2012-08-31 2015-03-30 Sutro Biopharma Inc Modified amino acids comprising an azido group
WO2014044873A1 (en) 2012-09-24 2014-03-27 Allozyne, Inc Amino acid derivatives
BR112015022641B1 (pt) 2013-03-15 2023-02-28 Medimmune Limited Construção de dna e processo de preparação de uma proteína-alvo
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US9764039B2 (en) * 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
CA2918064C (en) 2013-08-05 2022-04-26 Medimmune Limited Amino acid derivatives
EP3143154B1 (en) 2014-05-10 2020-01-29 Sorrento Therapeutics, Inc. Chemically-locked bispecific antibodies
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
JP2018500553A (ja) * 2014-12-05 2018-01-11 ネステク ソシエテ アノニム 患者試料における生物製剤の検出のための間接的均一移動度シフトアッセイ
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
IL321788A (en) 2015-02-04 2025-08-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
US10709839B2 (en) 2015-03-04 2020-07-14 Repro-Med Systems, Inc. Precision variable flow rate infusion system and method
US10906990B2 (en) 2015-08-19 2021-02-02 Riken Antibody with non-natural amino acid introduced therein
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN106924754B (zh) * 2015-12-30 2021-11-09 北京大学 聚氨基酸偶联物
SG11201806419RA (en) 2016-01-27 2018-08-30 Sutro Biopharma Inc Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CN110366557B (zh) * 2016-12-23 2024-04-09 威特拉公司 结合多肽及其制备方法
WO2018206715A2 (en) * 2017-05-09 2018-11-15 Cyano Biotech Gmbh Modified microcystins and nodularins
WO2019075487A1 (en) * 2017-10-13 2019-04-18 Ursure, Inc. Harvard Life Lab PRODUCTS AND METHODS FOR MONITORING ADHESION TO NUCLEOSIDE INHIBITOR THERAPY OF INVERSE TRANSCRIPTASE (NRTI)
CN110283249A (zh) * 2018-03-19 2019-09-27 江苏莱博德医疗科技有限公司 一种抗白介素6的人ScFv单链抗体
US20190292310A1 (en) * 2018-03-20 2019-09-26 Northeastern University Synthesis of high density molecular dna brushes via organic-phase ring-opening metathesis (co)polymerization
KR102480815B1 (ko) 2018-05-31 2022-12-26 글라이코넥스 인코포레이티드 바이안테나리 루이스 b 및 루이스 y 항원에 결합하는 치료 항체
AU2019356564A1 (en) * 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
US20200405883A1 (en) 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
US20230192824A1 (en) * 2020-04-02 2023-06-22 United States Of America As Represented By The Secretary Of The Navy Antigen Binding Proteins to Class 5 ETEC Adhesins
CN113203863B (zh) * 2021-04-28 2022-01-21 北京美联泰科生物技术有限公司 一种适用于白介素-6检测的缓冲液
CN113150122B (zh) * 2021-05-19 2023-03-17 上海儒克生物科技有限公司 高通量全兔源单克隆抗体的制备方法
IL308509A (en) 2021-05-24 2024-01-01 Vir Biotechnology Inc Transgenic polypeptides
CN115957319B (zh) * 2022-10-14 2023-06-30 北京东方百泰生物科技股份有限公司 一种抗nkg2a单克隆抗体的注射制剂
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
PL448731A1 (pl) * 2024-05-31 2025-12-01 Celon Pharma Spółka Akcyjna Przeciwciała bispecyficzne anty–IL-17A i anty-IL-6 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu chorób immunologicznych
CN119023961B (zh) * 2024-08-27 2026-02-03 首都医科大学附属北京朝阳医院 用于检测干眼病生物标志物的试剂及其制备方法和用途
CN120329434B (zh) * 2025-06-23 2025-10-21 杭州市第一人民医院(西湖大学附属杭州市第一人民医院) 一种mfge8单克隆抗体及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481038B1 (en) 1990-04-16 2002-10-02 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
GB9915247D0 (en) 1999-07-01 1999-09-01 Amat Limited Improvements relating to tyre degradation
US7405276B2 (en) 2000-11-01 2008-07-29 Elusys Therapeutics, Inc. Method of producing bispecific molecules by protein trans-splicing
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP2305312B1 (en) 2001-10-10 2015-03-04 ratiopharm GmbH Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
CA2500653A1 (en) 2002-10-16 2004-04-29 The Scripps Research Institute Glycoprotein synthesis
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20050287639A1 (en) 2004-05-17 2005-12-29 California Institute Of Technology Methods of incorporating amino acid analogs into proteins
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
TW200708792A (en) 2005-08-24 2007-03-01 Asia Optical Co Inc Retractable lens system and turnover lens-receiving mechanism thereof
WO2007130453A2 (en) 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
CN103396489A (zh) * 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
CN101668531B (zh) * 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2010027767A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
JP2012516158A (ja) * 2009-01-29 2012-07-19 メディミューン，エルエルシー 延長したインビボ半減期を有するヒト抗ｉｌ−６抗体ならびに腫瘍学、自己免疫疾患、および炎症性疾患の治療におけるそれらの使用

Similar Documents

Publication Publication Date Title
JP2013545438A5 (enExample)
AU2011237679B2 (en) TNF-alpha binding proteins
US20080227704A1 (en) CXCL13 binding proteins
HRP20191697T1 (hr) Vezujuće molekule za bcma i cd3
JP2018504105A5 (enExample)
IL245001B2 (en) Antibodies specific to cancer necrosis factor-like ligand 1a and preparations and their uses
RU2010129558A (ru) ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С АЛЬФА-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
JP2015535828A5 (enExample)
JP2015504306A5 (enExample)
JP2008520186A5 (enExample)
JP2011510654A5 (enExample)
JP2009502171A5 (enExample)
JP2015506912A5 (enExample)
JP2011527899A5 (enExample)
JP2014518883A5 (enExample)
JP2014534242A5 (enExample)
PE20120835A1 (es) Anticuerpos anti-tnf-alfa y sus usos
SI2753646T1 (en) Anti-CD40 antibodies, uses and methods
JP2020537520A5 (enExample)
RU2011115559A (ru) Антитела к cxcr4 и их применение для лечения рака
JP2021500916A5 (enExample)
JP2011505810A5 (enExample)
RU2012145232A (ru) Гуманизированные антитела к cxcr4 для лечения рака
JP2017508461A5 (enExample)
RU2016136639A (ru) Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины